Skip to content

Registry-based Evaluation of Symptom Outcomes and Long-term Validation of Traditional Chinese Medicine Efficacy for Post-PCI Chest Pain

Registry-based Evaluation of Symptom Outcomes and Long-term Validation of Traditional Chinese Medicine Efficacy for Post-PCI Chest Pain

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001282
Enrollment
Unknown
Registered
2025-06-27
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-PCI Chest Pain

Interventions

TCM add-on treatment group:TCM add-on treatment
Control group:Standard Treatment

Sponsors

Xiyuan Hospital China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients with unstable angina chronic coronary syndrome or coronary microcirculation disease who undergo elective or emergency coronary percutaneous coronary intervention (PCI). 2.Aged 18 to 80 years old regardless of gender. 3.Provided written informed consent and voluntarily agreed to participate in the study. 4.Capable of independently completing questionnaires and able to perform activities of daily living (ADLs) without assistance.

Exclusion criteria

Exclusion criteria: 1.Patients with malignant tumors or severe hematological disorders; severe liver dysfunction defined as alanine transaminase (ALT) or aspartate transaminase (AST) > 2× the upper limit of normal range or those with Child-Pugh class B/C cirrhosis; severe renal dysfunction defined as estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² or receiving dialysis. 2.Participants who have participated in or are scheduled to participate in another clinical trial within the past 1 month. 3.Pregnant or lactating women. 4.Patients with poor compliance as judged by investigators deemed unable to complete the trial. 5.Patients with known allergies to the components of Chinese herbal decoctions or patent medicines required for syndrome differentiation and treatment or their excipients. 6.Individuals who refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Seattle Angina Questionnaire (SAQ) Score;36-Item Short Form Health Survey (SF-36) Score;

Secondary

MeasureTime frame
Composite cardiovascular endpoints(cardiogenic death, all-cause mortality, acute myocardial infarction, repeat coronary revascularization, stroke, hospitalization for unstable angina, and heart failure);

Countries

China

Contacts

Public ContactHao Xu

Xiyuan Hospital China Academy of Chinese Medical Sciences

xuhaotcm@hotmail.com18601081161

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026